Progress of Ganovo and ritonavir combo on novel coronavirus pneumonia

10 March 2020

Chinese biotech Ascletis Pharma (HKEX: 1672) today announced the progress of the small sample clinical trial of hepatitis C treatment Ganovo (danoprevir) and ritonavir combination therapy on novel coronavirus pneumonia. The company’s shares edged up 1.63% to HK$3.73 by close of trading.

One of the treatment groups in this study is the group receiving oral Ganovo and ritonavir combination therapy, in which 10 novel coronavirus pneumonia patients were planned to be enrolled, and 11 patients actually enrolled.

All 11 patients receiving the oral Ganovo and ritonavir combination therapy have been discharged as they are satisfied with the discharge standards under the "Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6)" issued by the National Health Commission of the People's Republic of China.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK